Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.96 - $13.59 $565,160 - $964,890
71,000 Added 141.43%
121,200 $1.02 Million
Q1 2024

May 15, 2024

SELL
$13.56 - $20.78 $366,120 - $561,060
-27,000 Reduced 34.97%
50,200 $724,000
Q4 2023

Feb 14, 2024

BUY
$14.18 - $22.31 $287,854 - $452,893
20,300 Added 35.68%
77,200 $1.66 Million
Q3 2023

Nov 14, 2023

BUY
$18.22 - $25.85 $440,924 - $625,570
24,200 Added 74.01%
56,900 $1.09 Million
Q2 2023

Aug 14, 2023

BUY
$22.62 - $39.32 $377,754 - $656,644
16,700 Added 104.38%
32,700 $831,000
Q1 2023

May 15, 2023

SELL
$30.17 - $41.11 $340,921 - $464,543
-11,300 Reduced 41.39%
16,000 $578,000
Q4 2022

Feb 14, 2023

SELL
$36.43 - $49.4 $207,651 - $281,580
-5,700 Reduced 17.27%
27,300 $1.08 Million
Q3 2022

Nov 14, 2022

BUY
$40.66 - $53.03 $951,443 - $1.24 Million
23,400 Added 243.75%
33,000 $1.54 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $207M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.